HAE Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03

Harga $104.68

Kapitalisasi Pasar (MRQ) $4.76B

P/E (TTM) 50.6

EPS (TTM) $2.07

Pendapatan (TTM) $1.35B

ROE (TTM) 11.2%

D/E Utang/Ekuitas (MRQ) 1.4

Rentang 52M $48–$110

HAE Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04

rentang

batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Pemecahan saham 2

Tanggal ex-dividen	Pemecahan	Tipe
3 Des. 2012	2-for-1	Maju
11 Jan. 1993	2-for-1	Maju

Tentang Haemonetics Corporation Common Stock Tinjauan perusahaan dari Wikipedia

05 · wikidata

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.

Today, the company has expanded and has offices located in 16 countries. The company employs more than 1,800 people and markets its products in over 50 countries. Revenue is derived nearly equally from its three major markets -- Asia, Europe, and the Americas.

History

The company was founded in 1971. Haemonetics started out producing the containers and bags required for blood collection. The Latham Bowl was a disposable container that could automate the separation of blood by centrifugation. Through the 90's, the company added additional product lines and technologies. The company opened a manufacturing facility in Holbrook, Massachusetts in 1988.

In 1995 the company purchased the Intravenous Solutions manufacturing facility in Union, South Carolina.

Additional acquisitions grew the company and expanded its services. In the following years the company branched off to making the whole plasma collection station including the machine, supplies and software for plasma collection. These acquisitions included Edmonton-based Fifth Dimension (5D) Information Systems to gain entry into the blood and plasma software industry. Further acquisitions include Chicago-based Arryx in July 2006, Information Data Management, Inc. in January 2007, the acquisition of a division of Haemoscope in 2007, the acquisition of Infonale in July 2007, and, in 2009, Chico, California-based Altivation and Tucson, Arizona-based Sebra.

On August 21, 2007, 5D and IDM were officially merged into a new subsidiary called Haemonetics Software Solutions. The employees at both Edmonton (5D) and Rosemont (IDM) continue to work from their respective offices.

Further acquisitions included the April 2009 acquisition of Neoteric Technology Ltd and the April 2010 acquisition of California-based Global Med Technologies, Inc. Haemonetics acquired the Pall Corporation's transfusion medicine business on August 1, 2012 for ~$550 million.

In April 2024, it was announced Haemonetics had completed its acquisition of the Chicago-headquartered medical device temperature regulation manufacturer, Attune Medical for $160 million.

Product categories

Haemonetics products can be considered as belonging to two broad categories. Donor products (marketed to the blood donation industry, these include products that automate the blood donation process, automate the processing of blood, support pathogen inactivation and bacterial detection of blood, and test blood hematocrit); and products that are marketed to the surgical suite for blood loss management for patients. These products include surgical blood salvage (or "autotransfusion") devices, surgical field blood suction systems, and blood and patient warming systems.

Hemostasis

TEG 5000

Kaolin TEG

Kaolin TEG with Heparinase

RapidTEG

TEG Functional Fibrinogen

TEG PlateletMapping

TEG 6S

Baca selengkapnya Tampilkan lebih sedikit

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealth Care industriHealth Care karyawan3.009 negaraUS

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06

Pendapatan$1.33B

2017-04-01 → 2026-03-28

EPS$2.05

2017-04-01 → 2026-03-28

Arus Kas Bebas$260M

2017-04-01 → 2026-03-28

Margin bersih7.1%

2017-04-01 → 2026-03-28

Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik	HAE	rata-rata 5T	Median Rekan	Kesimpulan
P/E (TTM)	50.6rata-rata 5T ≈39.1	≈39.1	28.6	Terlalu mahal
P/S (TTM)	3.5rata-rata 5T ≈2.8	≈2.8	2.6	Nilai wajar
P/B (MRQ)	5.7rata-rata 5T ≈4.2	≈4.2	2.1	Terlalu mahal
EV / EBITDA	36.5rata-rata 5T ≈29.3	≈29.3	17.9	Terlalu mahal
Harga / FCF (TTM)	16.3rata-rata 5T ≈27.4	≈27.4	·	·
Harga / Arus Kas (TTM)	14.5rata-rata 5T ≈16.6	≈16.6	17.6	Kurang nilai
EV / Revenue (EV / Pendapatan)	4.3rata-rata 5T ≈3.4	≈3.4	·	·
EV / FCF	21.9rata-rata 5T ≈32.5	≈32.5	·	·
Harga / Nilai Buku Berwujud (MRQ)	11.8	·	·	·
PEG Ratio (Rasio PEG)	≈8.8	·	·	·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC

Metrik	HAE	rata-rata 5T	Median Rekan	Kesimpulan
Margin Kotor (TTM)	59.0%rata-rata 5T ≈54.1%	≈54.1%	55.0%	Sejajar
Margin Operasi (TTM)	11.9%rata-rata 5T ≈12.4%	≈12.4%	14.5%	Tingkat teratas
EBITDA Margin (Margin EBITDA)	11.8%rata-rata 5T ≈12.4%	≈12.4%	17.6%	Sejajar
Margin Sebelum Pajak (TTM)	9.6%rata-rata 5T ≈11.1%	≈11.1%	13.1%	Sejajar
Margin Laba Bersih (TTM)	7.1%rata-rata 5T ≈8.6%	≈8.6%	9.5%	Sejajar
ROA (TTM)	4.0%rata-rata 5T ≈5.1%	≈5.1%	3.5%	Sejajar
ROE (TTM)	11.2%rata-rata 5T ≈12.8%	≈12.8%	6.5%	Tingkat teratas
ROIC	5.9%rata-rata 5T ≈6.7%	≈6.7%	5.1%	Tingkat teratas

Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca

Metrik	HAE	rata-rata 5T	Median Rekan	Kesimpulan
Utang / Ekuitas (MRQ)	1.4rata-rata 5T ≈1.2	≈1.2	0.4	Utang tinggi
Rasio Lancar (MRQ)	3.1rata-rata 5T ≈2.4	≈2.4	2.7	Likuiditas kuat
Quick Ratio (Rasio Cepat)	1.6rata-rata 5T ≈1.3	≈1.3	1.4	Likuiditas kuat
Utang Jangka Panjang / Ekuitas (MRQ)	1.4rata-rata 5T ≈1.0	≈1.0	0.4	Utang tinggi

Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T

Metrik	HAE	rata-rata 5T	Median Rekan	Kesimpulan
Revenue YoY (Pendapatan YoY)	-2.0%rata-rata 5T ≈9.2%	≈9.2%	·	·
Revenue CAGR 3Y (CAGR Pendapatan 3T)	4.5%rata-rata 5T ≈10.0%	≈10.0%	·	·
Revenue CAGR 5Y (CAGR Pendapatan 5T)	8.9%	·	·	·
EPS YoY	-38.1%rata-rata 5T ≈25.9%	≈25.9%	·	·
Net Income YoY (Laba Bersih YoY)	-42.0%rata-rata 5T ≈24.6%	≈24.6%	·	·
EPS CAGR 3Y (CAGR EPS 3T)	-2.9%rata-rata 5T ≈23.0%	≈23.0%	·	·
EPS CAGR 5Y (CAGR EPS 5T)	5.8%	·	·	·
Net Income CAGR 3Y (CAGR Laba Bersih 3T)	-5.5%rata-rata 5T ≈21.8%	≈21.8%	·	·
Net Income CAGR 5Y (CAGR Laba Bersih 5T)	4.1%	·	·	·

Metrik Per Saham EPS, nilai buku per saham, arus kas per saham, dividen per saham

Metrik	HAE	rata-rata 5T	Median Rekan	Kesimpulan
EPS (Diluted)	$2.05rata-rata 5T ≈$2.15	≈$2.15	·	·
Revenue / Share (Pendapatan / Saham)	$28.17rata-rata 5T ≈$24.51	≈$24.51	·	·
Cash Flow / Share (Arus Kas / Saham)	$6.19rata-rata 5T ≈$4.40	≈$4.40	·	·
Cash / Share (Kas / Saham)	$5.42rata-rata 5T ≈$5.20	≈$5.20	·	·

Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang

Metrik	HAE	rata-rata 5T	Median Rekan	Kesimpulan
Asset Turnover (Perputaran Aset)	0.6rata-rata 5T ≈0.6	≈0.6	0.6	Lemah
Inventory Turnover (Perputaran Persediaan)	1.6rata-rata 5T ≈1.8	≈1.8	2.9	Lemah
Receivables Turnover (Perputaran Piutang)	6.4rata-rata 5T ≈6.7	≈6.7	6.4	Sejajar
Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.)	≈$443.3K	·	·	·

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14

Kejutan Rata-rata 5.0%

Laporan Berikutnya Nov 04, 2026

Periode	Laporan	EPS Aktual	EPS Estimasi	Kejutan
31 Maret 2027	Agu 5, 2026	$1.14	$1.09	4.8%
30 Juni 2026		$1.14	$1.09	4.8%
31 Maret 2026		$1.29	$1.28	0.42%
31 Des. 2025		$1.31	$1.26	3.7%
30 Sep. 2025		$1.27	$1.12	13.3%
30 Juni 2025		$1.10	$1.03	7.2%
31 Maret 2025		$1.24	$1.23	0.62%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15

Laporan Laba Rugi 16

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$1.33B	$1.36B	$1.31B	$1.17B	$993M	$870M	$988M	$968M	$904M	$886M	$909M	$910M
Cost of Revenue	$546M	$612M	$618M	$554M	$488M	$473M	$504M	$550M	$492M	$508M	$503M	$476M
Gross Profit	$788M	$749M	$692M	$615M	$506M	$398M	$485M	$418M	$412M	$378M	$406M	$434M
R&D Expense	$60M	$63M	$54M	$50M	$47M	$33M	$31M	$36M	$39M	$38M	$45M	$54M
SG&A Expense	$442M	$437M	$430M	$377M	$340M	$275M	$282M	$273M	$317M	$302M	$317M	$337M
Operating Expenses	$631M	$527M	$527M	$459M	$425M	$308M	$381M	$334M	$356M	$398M	$450M	$394M
Operating Income	$157M	$222M	$165M	$156M	$81M	$90M	$103M	$84M	$56M	$-19M	$-44M	$41M
Other Non-op	$-29M	$-10M	$-13M	$-15M	$-17M	$-17M	$-16M	$-10M	$-5M	$-8M	$-9M	$-9M
Pretax Income	$128M	$212M	$152M	$141M	$64M	$73M	$87M	$74M	$60M	$-27M	$-53M	$31M
Income Tax	$31M	$44M	$34M	$26M	$20M	$-7M	$11M	$19M	$14M	$-1M	$2M	$14M
Net Income	$97M	$168M	$118M	$115M	$43M	$79M	$77M	$55M	$46M	$-26M	$-56M	$17M
EPS (Basic)	$2.06	$3.33	$2.32	$2.27	$0.85	$1.57	$1.51	$1.07	$0.86	$-0.51	$-1.09	$0.33
EPS (Diluted)	$2.05	$3.31	$2.29	$2.24	$0.84	$1.55	$1.48	$1.04	$0.85	$-0.51	$-1.09	$0.32
Shares (Basic)	47,179,000	50,330,000	50,706,000	50,783,000	51,047,000	50,688,000	50,692,000	51,533,000	52,755,000	51,524,000	50,910,000	51,533,000
Shares (Diluted)	47,354,000	50,730,000	51,397,000	51,420,000	51,353,000	51,292,000	51,815,000	52,942,000	53,501,000	51,524,000	50,910,000	52,089,000
EBITDA	$157M	$222M	$165M	$156M	$81M	$90M	$103M	$84M	$56M	$-19M	$-44M	$41M

Neraca 25

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Equivalents	$245M	$307M	$179M	$284M	$259M	$192M	$137M	$169M	$180M	$140M	$115M	$161M
Receivables	$217M	$203M	$207M	$179M	$159M	$128M	$165M	$185M	$151M	$153M	$157M	$146M
Inventory	$306M	$365M	$317M	$259M	$293M	$323M	$270M	$194M	$161M	$177M	$187M	$211M
Prepaid Expense	$66M	$60M	$66M	$47M	$44M	$51M	$31M	$27M	$29M	$41M	$29M	$40M
Current Assets	$835M	$935M	$769M	$770M	$756M	$694M	$604M	$576M	$521M	$510M	$488M	$558M
PP&E (Net)	$306M	$284M	$311M	$311M	$258M	$218M	$253M	$344M	$332M	$324M	$338M	$322M
PP&E (Gross)	$842M	$837M	$959M	$944M	$869M	$817M	$832M	$933M	$873M	$807M	$786M	$732M
Accum. Depreciation	$536M	$553M	$648M	$633M	$611M	$600M	$579M	$589M	$541M	$484M	$449M	$410M
Goodwill	$656M	$604M	$565M	$466M	$467M	$466M	$211M	$211M	$211M	$211M	$268M	$334M
Intangibles	$448M	$456M	$406M	$276M	$310M	$365M	$133M	$128M	$157M	$178M	$204M	$245M
Other Non-current Assets	$142M	$164M	$136M	$107M	$63M	$71M	$62M	$12M	$12M	$12M	$14M	$11M
Total Assets	$2.40B	$2.45B	$2.20B	$1.93B	$1.86B	$1.82B	$1.27B	$1.27B	$1.24B	$1.24B	$1.32B	$1.49B
Accounts Payable	$51M	$67M	$73M	$64M	$58M	$50M	$51M	$63M	$55M	$43M	$40M	$48M
Current Liabilities	$283M	$578M	$300M	$252M	$442M	$253M	$275M	$236M	$385M	$211M	$186M	$189M
Capital Leases	$41M	$50M	$58M	$56M	$56M	$63M	$52M	·	·	·	·	·
Deferred Tax	$38M	$63M	$63M	$36M	$29M	$44M	$11M	$20M	$7M	$12M	$21M	$33M
Other Non-current Liabilities	$59M	$68M	$75M	$75M	$80M	$100M	$89M	$29M	$34M	$22M	$26M	$32M
Long-term Debt	$1.24B	$1.22B	$808M	$766M	$774M	$708M	$382M	$350M	$254M	$316M	$408M	$430M
Total Debt	$1.22B	$1.22B	$808M	$766M	$774M	$708M	$382M	$350M	$254M	$315M	$408M	$428M
Common Stock	$453.0K	$482.0K	$508.0K	$504.0K	$511.0K	$509.0K	$503.0K	$510.0K	$523.0K	$523.0K	$509.0K	$517.0K
Retained Earnings	$279M	$352M	$360M	$253M	$202M	$158M	$79M	$161M	$267M	$290M	$316M	$420M
AOCI	$-38M	$-55M	$-36M	$-30M	$-26M	$-30M	$-45M	$-30M	$-19M	$-33M	$-35M	$-22M
Stockholders' Equity	$796M	$821M	$960M	$818M	$749M	$732M	$587M	$668M	$752M	$740M	$722M	$826M
Liabilities + Equity	$2.40B	$2.45B	$2.20B	$1.93B	$1.86B	$1.82B	$1.27B	$1.27B	$1.24B	$1.24B	$1.32B	$1.49B
Shares Outstanding	45,252,667	48,215,899	50,787,859	50,448,519	51,124,240	50,868,820	50,322,930	51,019,918	52,342,965	52,255,495	50,932,348	51,670,969

Arus Kas 16

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
D&A	$112M	$116M	$97M	$93M	$98M	$84M	$110M	$109M	$89M	$90M	$90M	$86M
Stock-based Comp	$34M	$30M	$28M	$26M	$24M	$26M	$20M	$17M	$13M	$9M	$7M	$14M
Deferred Tax	$-26M	$-6M	$-11M	$6M	$5M	$-21M	$-7M	$13M	$-6M	$-7M	$-1M	$4M
Amort. of Intangibles	$50M	$56M	$41M	$42M	$57M	$41M	$34M	$25M	$32M	$37M	$59M	$34M
Restructuring	$3M	$14M	$14M	$657.0K	$4M	$1M	$4M	$395.0K	$31M	$22M	$23M	$37M
Operating Cash Flow	$293M	$182M	$182M	$273M	$172M	$109M	$158M	$159M	$220M	$160M	$122M	$127M
CapEx	$33M	$39M	$38M	$191M	$97M	$37M	$49M	$119M	$75M	$76M	$102M	$122M
Investing Cash Flow	$-180M	$-162M	$-322M	$-144M	$-86M	$-425M	$-57M	$-116M	$-63M	$-73M	$-105M	$-122M
Debt Issued	·	·	·	·	·	·	$0	$348M	$0	$0	·	$0
Net Debt Issued	·	$-5M	$-12M	$-10M	$-18M	$-22M	$-13M	$81M	$-62M	$-43M	$-21M	$-9M
Stock Repurchased	$175M	$225M	$0	$75M	$0	$0	$175M	$160M	$100M	$0	$61M	$39M
Net Stock Activity	$-175M	$-225M	$0	$-75M	$0	$0	$-175M	$-160M	$-100M	$0	$-61M	$-39M
Financing Cash Flow	$-178M	$109M	$38M	$-100M	$-16M	$367M	$-131M	$-51M	$-121M	$-60M	$-63M	$-33M
Net Change in Cash	$-61M	$128M	$-106M	$25M	$67M	$55M	$-32M	$-11M	$41M	$24M	$-46M	$-32M
Taxes Paid	$61M	·	·	·	·	$12M	$12M	$8M	$9M	$7M	$8M	$11M
Free Cash Flow	$260M	$142M	$115M	$163M	$76M	$72M	$109M	$40M	$146M	$84M	$19M	$5M

Profitabilitas 8

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Gross Margin	59.0%	55.0%	52.8%	52.6%	50.9%	45.7%	49.0%	43.1%	45.6%	42.7%	44.7%	47.7%
Operating Margin	11.8%	16.3%	12.6%	13.4%	8.1%	10.3%	10.5%	8.6%	6.2%	-2.2%	-4.8%	4.5%
Net Margin	7.3%	12.3%	9.0%	9.9%	4.4%	9.1%	7.7%	5.7%	5.0%	-3.0%	-6.1%	1.9%
Pretax Margin	9.6%	15.6%	11.6%	12.1%	6.4%	8.4%	8.8%	7.6%	6.6%	-3.1%	-5.9%	3.4%
EBITDA Margin	11.8%	16.3%	12.6%	13.4%	8.1%	10.3%	10.5%	8.6%	6.2%	-2.2%	-4.8%	4.5%
ROA	4.0%	7.2%	5.7%	6.1%	2.4%	5.1%	6.0%	4.4%	3.7%	-2.1%	-4.0%	1.1%
ROE	11.8%	19.4%	12.3%	14.5%	5.9%	11.0%	13.2%	8.7%	6.1%	-3.6%	-7.2%	2.0%
ROIC	5.9%	8.6%	7.2%	8.0%	3.6%	6.8%	9.4%	6.1%	4.3%	-1.8%	-4.0%	1.8%

Likuiditas & Solvabilitas 4

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Current Ratio	3.0	1.6	2.6	3.1	1.7	2.7	2.2	2.4	1.4	2.4	2.6	3.0
Quick Ratio	1.6	0.9	1.3	1.8	0.9	1.3	1.1	1.5	0.9	1.4	1.5	1.6
Debt / Equity	1.5	1.5	0.8	0.9	1.0	1.0	0.7	0.5	0.3	0.4	0.6	0.5
LT Debt / Equity	1.5	1.1	0.8	0.9	0.7	0.9	0.5	0.5	0.1	0.3	0.5	0.5

Efisiensi 3

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Asset Turnover	0.6	0.6	0.6	0.6	0.5	0.6	0.8	0.8	0.7	0.7	0.6	0.6
Inventory Turnover	1.6	1.8	2.1	2.0	1.6	1.6	2.2	3.1	2.9	2.8	2.5	2.3
Receivables Turnover	6.4	6.7	6.8	6.9	6.9	5.9	5.6	5.8	5.9	5.7	6.0	5.9

Per Saham 5

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Book Value / Share	$17.60	$17.02	$18.90	$16.21	$14.66	$14.38	$11.67	$13.09	$14.38	$14.15	$14.17	$15.99
Revenue / Share	$28.17	$26.82	$25.47	$22.73	$19.34	$16.97	$19.08	$18.28	$16.90	$17.20	$17.85	$17.48
Cash Flow / Share	$6.19	$3.58	$3.54	$5.31	$3.35	$2.12	$3.05	$3.01	$4.12	$3.10	$2.39	$2.44
Cash / Share	$5.42	$6.36	$3.52	$5.64	$5.08	$3.78	$2.73	$3.32	$3.44	$2.67	$2.26	$3.11
EPS (TTM)	$2.05	$3.31	$2.29	$2.24	$0.84	$1.55	$1.48	$1.04	$0.85	$-0.51	$-1.09	$0.32

Tingkat Pertumbuhan 9

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue YoY	-2.0%	4.0%	12.0%	17.7%	14.1%	·	·	·	·	·	·	·
Revenue CAGR 3Y	4.5%	11.1%	14.6%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	8.9%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	-38.1%	44.5%	2.2%	166.7%	-45.8%	·	·	·	·	·	·	·
EPS CAGR 3Y	-2.9%	58.0%	13.9%	·	·	·	·	·	·	·	·	·
EPS CAGR 5Y	5.8%	·	·	·	·	·	·	·	·	·	·	·
Net Income YoY	-42.0%	42.6%	1.9%	166.1%	-45.4%	·	·	·	·	·	·	·
Net Income CAGR 3Y	-5.5%	56.9%	13.9%	·	·	·	·	·	·	·	·	·
Net Income CAGR 5Y	4.1%	·	·	·	·	·	·	·	·	·	·	·

Valuasi (TTM) 14

Metrik	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue TTM	$1.33B	$1.36B	$1.31B	$1.17B	$993M	$870M	$988M	$968M	$904M	$886M	$909M	$910M
Net Income TTM	$97M	$168M	$118M	$115M	$43M	$79M	$77M	$55M	$46M	$-26M	$-56M	$17M
Market Cap	$2.45B	$3.05B	$4.33B	$4.17B	$3.26B	$5.70B	$5.08B	$4.46B	$3.83B	$2.12B	$1.80B	$2.28B
Enterprise Value	$3.42B	$3.96B	$4.96B	$4.66B	$3.78B	$6.21B	$5.33B	$4.64B	$3.90B	$2.30B	$2.09B	$2.55B
P/E	26.4	19.1	37.3	36.9	76.0	72.3	68.2	84.1	86.1	-79.5	-32.4	138.2
P/S	1.8	2.2	3.3	3.6	3.3	6.5	5.1	4.6	4.2	2.4	2.0	2.5
P/B	3.1	3.7	4.5	5.1	4.4	7.8	8.7	6.7	5.1	2.9	2.5	2.8
P / Tangible Book	·	·	·	54.9	·	·	·	·	·	·	·	·
P / Cash Flow	8.3	16.8	23.8	15.3	18.9	52.4	32.1	28.0	17.4	13.3	14.7	18.0
P / FCF	9.4	21.4	37.5	25.6	43.1	79.4	46.4	110.7	26.3	25.4	92.4	460.7
EV / EBITDA	21.8	17.9	30.1	29.8	46.8	69.2	51.5	55.6	69.5	-118.4	-47.6	62.9
EV / FCF	13.1	27.8	43.0	28.6	49.9	86.6	48.7	115.2	26.8	27.5	107.4	514.6
EV / Revenue	2.6	2.9	3.8	4.0	3.8	7.1	5.4	4.8	4.3	2.6	2.3	2.8
Earnings Yield	3.8%	5.2%	2.7%	2.7%	1.3%	1.4%	1.5%	1.2%	1.2%	-1.3%	-3.1%	0.72%

Laporan Laba Rugi 16

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
Revenue	$339M	$346M	$339M	$327M	$321M	$331M	$349M	$346M	$336M	$343M	$336M	$318M	$340M	$305M	$297M
Cost of Revenue	$137M	$148M	$137M	$133M	$129M	$138M	$155M	$158M	$161M	$167M	$158M	$148M	$169M	$147M	$140M
Gross Profit	$203M	$198M	$202M	$195M	$192M	$193M	$194M	$187M	$175M	$176M	$178M	$171M	$172M	$159M	$158M
R&D Expense	$16M	$14M	$14M	$15M	$16M	$18M	$16M	$14M	$14M	$16M	$13M	$13M	$16M	$13M	$11M
SG&A Expense	$119M	$121M	$109M	$102M	$111M	$115M	$106M	$107M	$108M	$109M	$112M	$115M	$98M	$95M	$92M
Operating Expenses	$145M	$221M	$135M	$136M	$138M	$122M	$135M	$136M	$135M	$146M	$132M	$135M	$121M	$115M	$111M
Operating Income	$57M	$-23M	$67M	$58M	$54M	$71M	$59M	$52M	$40M	$30M	$46M	$35M	$51M	$43M	$47M
Other Non-op	$-10M	$-5M	$-7M	$-7M	$-9M	$-598.0K	$-9M	$-7M	$7M	$-7M	$-2M	$-2M	$-3M	$-1M	$-6M
Pretax Income	$48M	$-28M	$60M	$51M	$45M	$71M	$50M	$45M	$47M	$23M	$44M	$33M	$48M	$42M	$41M
Income Tax	$15M	$-8M	$15M	$13M	$11M	$13M	$12M	$11M	$8M	$3M	$13M	$8M	$5M	$9M	$8M
Net Income	$33M	$-20M	$45M	$39M	$34M	$58M	$37M	$34M	$38M	$20M	$31M	$25M	$42M	$33M	$33M
EPS (Basic)	$0.73	$-0.42	$0.96	$0.81	$0.71	$1.17	$0.75	$0.66	$0.75	$0.40	$0.62	$0.49	$0.84	$0.65	$0.65
EPS (Diluted)	$0.72	$-0.41	$0.95	$0.81	$0.70	$1.17	$0.74	$0.66	$0.74	$0.40	$0.61	$0.48	$0.84	$0.64	$0.64
Shares (Basic)	45,361,000	·	46,792,000	47,590,000	48,111,000	·	50,286,000	50,898,000	50,943,000	·	50,768,000	50,727,000	·	50,509,000	50,953,000
Shares (Diluted)	45,704,000	·	46,987,000	47,664,000	48,353,000	·	50,639,000	51,240,000	51,564,000	·	51,445,000	51,396,000	·	51,219,000	51,558,000
EBITDA	$57M	·	$67M	$58M	$54M	·	$59M	$52M	$40M	·	$46M	$35M	·	$43M	$47M

Neraca 25

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
Cash & Equivalents	$223M	$245M	$363M	$296M	$293M	$307M	$321M	$299M	$344M	$179M	$194M	$351M	·	$224M	$241M
Receivables	$216M	$217M	$196M	$207M	$201M	$203M	$212M	$214M	$201M	$207M	$212M	$174M	·	$181M	$172M
Inventory	$307M	$306M	$321M	$336M	$361M	$365M	$360M	$382M	$374M	$317M	$304M	$286M	·	$256M	$255M
Prepaid Expense	$65M	$66M	$63M	$60M	$59M	$60M	$113M	$61M	$59M	$66M	$55M	$55M	·	$45M	$48M
Current Assets	$811M	$835M	$944M	$900M	$913M	$935M	$1.01B	$956M	$979M	$769M	$765M	$866M	·	$706M	$716M
PP&E (Net)	$304M	$306M	$297M	$292M	$287M	$284M	$286M	$300M	$302M	$311M	$319M	$308M	·	$313M	$308M
PP&E (Gross)	$854M	$842M	$837M	$815M	$795M	$837M	$867M	$939M	$949M	$959M	$979M	$950M	·	·	·
Accum. Depreciation	$550M	$536M	$540M	$523M	$508M	$553M	$581M	$639M	$647M	$648M	$661M	$642M	·	·	·
Goodwill	$657M	$656M	$607M	$606M	$607M	$604M	$605M	$616M	$613M	$565M	$555M	$465M	$466M	$466M	$465M
Intangibles	$435M	$448M	$420M	$428M	$451M	$456M	$466M	$488M	$495M	$406M	$429M	$251M	·	$284M	$293M
Other Non-current Assets	$150M	$142M	$216M	$208M	$196M	$164M	$160M	$156M	$142M	$136M	$127M	$117M	·	$103M	$80M
Total Assets	$2.37B	$2.40B	$2.49B	$2.44B	$2.46B	$2.45B	$2.53B	$2.53B	$2.54B	$2.20B	$2.20B	$2.01B	·	$1.88B	$1.87B
Accounts Payable	$56M	$51M	$49M	$62M	$46M	$67M	$63M	$69M	$77M	$73M	$57M	$80M	·	$64M	$61M
Current Liabilities	$263M	$283M	$540M	$548M	$531M	$578M	$253M	$274M	$260M	$300M	$262M	$264M	·	$227M	$262M
Capital Leases	·	$41M	·	·	·	$50M	·	·	·	$58M	·	·	·	·	·
Deferred Tax	$39M	$38M	$56M	$58M	$59M	$63M	$61M	$63M	$65M	$63M	$62M	$35M	·	$40M	$36M
Other Non-current Liabilities	$57M	$59M	$64M	$66M	$68M	$68M	$90M	$90M	$92M	$75M	$76M	$70M	·	$78M	$78M
Long-term Debt	$1.19B	$1.24B	$1.22B	$1.22B	$1.22B	$1.25B	$1.22B	$1.22B	$1.22B	$808M	$871M	$762M	·	$767M	$818M
Total Debt	$1.17B	·	$1.22B	$1.22B	$1.22B	·	$1.22B	$1.22B	$1.22B	·	$871M	$762M	·	$767M	$818M
Common Stock	$455.0K	$453.0K	$468.0K	$467.0K	$482.0K	$482.0K	$502.0K	$504.0K	$512.0K	$508.0K	$508.0K	$507.0K	·	$504.0K	$506.0K
Retained Earnings	$312M	$279M	$381M	$336M	$356M	$352M	$392M	$369M	$387M	$360M	$340M	$309M	·	$224M	$204M
AOCI	$-42M	$-38M	$-35M	$-41M	$-36M	$-55M	$-56M	$-35M	$-43M	$-36M	$-24M	$-33M	·	$-36M	$-40M
Stockholders' Equity	$837M	$796M	$911M	$849M	$882M	$821M	$907M	$879M	$905M	$960M	$943M	$894M	$818M	$776M	$729M
Liabilities + Equity	$2.37B	$2.40B	$2.49B	$2.44B	$2.46B	$2.45B	$2.53B	$2.53B	$2.54B	$2.20B	$2.20B	$2.01B	·	$1.88B	$1.87B
Shares Outstanding	45,471,313	45,252,667	46,829,249	46,747,381	48,158,723	48,215,899	50,235,051	50,381,127	51,152,886	50,787,859	50,785,040	50,740,389	·	50,444,470	50,605,499

Arus Kas 13

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
D&A	$27M	$27M	$27M	$28M	$29M	$28M	$29M	$29M	$29M	$28M	$24M	·	$24M	$24M	·
Stock-based Comp	$9M	$9M	$8M	$8M	$9M	$7M	$8M	$7M	$8M	$7M	$7M	·	$7M	$7M	·
Deferred Tax	$668.0K	$-20M	$-2M	$-725.0K	$-3M	$3M	$-2M	$-2M	$-4M	$-6M	$-3M	·	·	·	·
Amort. of Intangibles	$12M	$12M	$12M	$13M	$13M	$13M	$14M	$14M	$14M	$13M	$9M	$9M	$15M	$10M	$11M
Restructuring	$2M	$196.0K	$1M	$204.0K	$1M	$984.0K	$4M	$5M	$5M	$6M	$8M	$86.0K	$701.0K	$44.0K	$165.0K
Operating Cash Flow	$52M	$71M	$94M	$111M	$17M	$117M	$44M	$49M	$-27M	$64M	$-540.0K	·	$80M	$64M	·
CapEx	$8M	$18M	$6M	$5M	$4M	$16M	$9M	$9M	$6M	$7M	$-3M	·	$93M	$17M	·
Investing Cash Flow	$-22M	$-87M	$-29M	$-30M	$-33M	$18M	$-17M	$-23M	$-139M	$-13M	$-269M	·	$-18M	$-36M	·
Net Debt Issued	$-2M	·	·	·	$-2M	·	·	·	$-2M	·	·	·	·	·	·
Stock Repurchased	·	$100M	$0	·	·	$150M	$0	·	·	$0	$0	·	$0	$0	·
Financing Cash Flow	$-52M	$-101M	$2M	$-77M	$-2M	$-151M	$1M	$-75M	$334M	$-64M	$109M	·	$-2M	$-50M	·
Net Change in Cash	$-22M	$-118M	$67M	$4M	$-14M	$-14M	$22M	$-45M	$166M	$-15M	$-157M	·	$60M	$-17M	·
Free Cash Flow	$44M	·	·	·	$14M	·	·	·	$-33M	·	·	·	·	·	·

Profitabilitas 8

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
Gross Margin	59.8%	·	59.7%	59.5%	59.8%	·	55.5%	54.2%	52.0%	·	52.9%	53.6%	·	52.0%	53.1%
Operating Margin	16.9%	·	19.9%	17.9%	16.8%	·	16.9%	15.0%	11.8%	·	13.7%	11.1%	·	14.2%	15.7%
Net Margin	9.7%	·	13.2%	11.8%	10.6%	·	10.8%	9.8%	11.4%	·	9.3%	7.8%	·	10.8%	11.2%
Pretax Margin	14.0%	·	17.7%	15.7%	14.1%	·	14.3%	12.9%	13.9%	·	13.1%	10.3%	·	13.8%	13.8%
EBITDA Margin	16.9%	·	19.9%	17.9%	16.8%	·	16.9%	15.0%	11.8%	·	13.7%	11.1%	·	14.2%	15.7%
ROA	1.4%	·	1.8%	1.6%	1.4%	·	1.6%	1.5%	1.7%	·	1.5%	1.3%	·	1.8%	1.8%
ROE	3.8%	·	4.9%	4.5%	3.8%	·	4.0%	3.8%	4.3%	·	3.6%	3.1%	·	4.4%	4.7%
ROIC	2.0%	·	2.4%	2.1%	1.9%	·	2.1%	1.9%	1.5%	·	1.8%	1.6%	·	2.2%	2.4%

Likuiditas & Solvabilitas 4

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
Current Ratio	3.1	·	1.7	1.6	1.7	·	4.0	3.5	3.8	·	2.9	3.3	·	3.1	2.7
Quick Ratio	1.7	·	1.0	0.9	0.9	·	2.1	1.9	2.1	·	1.5	2.0	·	1.8	1.6
Debt / Equity	1.4	·	1.3	1.4	1.4	·	1.4	1.4	1.4	·	0.9	0.9	·	1.0	1.1
LT Debt / Equity	1.4	·	1.0	1.1	1.0	·	1.3	1.4	1.3	·	0.9	0.8	·	1.0	1.0

Efisiensi 3

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
Asset Turnover	0.1	·	0.1	0.1	0.1	·	0.1	0.2	0.1	·	0.2	0.2	·	0.2	0.2
Inventory Turnover	0.4	·	0.4	0.4	0.4	·	0.5	0.5	0.5	·	0.6	0.5	·	0.5	0.5
Receivables Turnover	1.6	·	1.7	1.6	1.6	·	1.6	1.8	1.8	·	1.7	1.8	·	1.8	1.9

Per Saham 5

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
Book Value / Share	$18.41	·	$19.46	$18.17	$18.32	·	$18.05	$17.44	$17.70	·	$18.57	$17.61	·	$15.38	$14.41
Revenue / Share	$7.43	·	$7.21	$6.87	$6.65	·	$6.88	$6.74	$6.52	·	$6.54	$6.19	·	$5.96	$5.77
Cash Flow / Share	$1.14	·	·	·	$0.36	·	·	·	$-0.53	·	·	·	·	·	·
Cash / Share	$4.91	·	$7.76	$6.34	$6.08	·	$6.39	$5.94	$6.73	·	$3.82	$6.92	·	$4.44	$4.77
EPS (TTM)	$2.07	·	$3.63	$3.42	$3.27	·	$2.54	$2.41	$2.23	·	$2.73	$2.76	·	·	·

Valuasi (TTM) 11

Metrik	Q1 2027	Q4 2026	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q4 2023	Q3 2023	Q2 2023
Revenue TTM	$1.35B	·	$1.32B	$1.33B	$1.35B	·	$1.37B	$1.36B	$1.33B	·	$1.31B	$1.28B	·	·	·
Net Income TTM	$96M	·	$175M	$168M	$163M	·	$130M	$124M	$115M	·	$140M	$141M	·	·	·
Market Cap	$3.51B	·	$3.76B	$2.25B	$3.55B	·	$3.90B	$4.02B	$4.23B	·	$4.34B	$4.55B	·	$3.97B	$3.75B
Enterprise Value	$4.47B	·	$4.62B	$3.18B	$4.49B	·	$4.80B	$4.95B	$5.11B	·	$5.02B	$4.96B	·	$4.51B	$4.32B
P/E	37.3	·	22.1	14.1	22.6	·	30.5	33.1	37.1	·	31.3	32.5	·	·	·
P/S	2.6	·	2.9	1.7	2.6	·	2.8	3.0	3.2	·	3.3	3.6	·	·	·
P/B	4.2	·	4.1	2.7	4.0	·	4.3	4.6	4.7	·	4.6	5.1	·	5.1	5.1
P / Tangible Book	·	·	·	·	·	·	·	·	·	·	·	25.6	·	155.7	·
P / Cash Flow	67.2	·	·	·	204.3	·	·	·	-154.3	·	·	·	·	·	·
EV / Revenue	3.3	·	3.5	2.4	3.3	·	3.5	3.6	3.8	·	3.8	3.9	·	·	·
Earnings Yield	2.7%	·	4.5%	7.1%	4.4%	·	3.3%	3.0%	2.7%	·	3.2%	3.1%	·	·	·

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16

Metrik	2026-03-28	2025-03-29	2024-03-30	2023-04-01	2022-04-02
Pendapatan	$1.33B	$1.36B	$1.31B	$1.17B	$993M
Margin Kotor %	59.0%	55.0%	52.8%	52.6%	50.9%
Margin Operasi %	11.8%	16.3%	12.6%	13.4%	8.1%
Laba Bersih	$97M	$168M	$118M	$115M	$43M
EPS Dilusian	$2.05	$3.31	$2.29	$2.24	$0.84

Metrik	2026-03-28	2025-03-29	2024-03-30	2023-04-01	2022-04-02
Utang / Ekuitas	1.5	1.5	0.8	0.9	1.0
Rasio Lancar	3.0	1.6	2.6	3.1	1.7
Rasio Cepat	1.6	0.9	1.3	1.8	0.9

Metrik	2026-03-28	2025-03-29	2024-03-30	2023-04-01	2022-04-02
Arus Kas Bebas	$260M	$142M	$115M	$163M	$76M

Pemilik institusional (13F) 361 pengaju · $4.0B total · Per tanggal 30 Sep. 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 361

Nilai yang dipegang $4.0B

Posisi baru 57

Posisi yang keluar 43

Aktivitas institusional — Q2 2026 vs kuartal sebelumnya

Posisi baru	Posisi yang keluar	Meningkat	Menurun	Perubahan bersih saham
57 (-3 vs Kuartal sebelumnya)	43 (-12 vs Kuartal sebelumnya)	108 (-8 vs Kuartal sebelumnya)	122 (+10 vs Kuartal sebelumnya)	+2.2M

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi	Nilai	Saham	% dari 13F yang dilacak	Tipe
BlackRock, Inc.	$443.194.350	5.909.258	11,13%	Saham
VANGUARD GROUP INC	$381.604.971	4.761.135	9,58%	Saham
NEUBERGER BERMAN GROUP LLC	$313.473.399	4.179.443	7,87%	Saham
VANGUARD PORTFOLIO MANAGEMENT LLC	$190.979.550	2.546.394	4,79%	Saham
AQR CAPITAL MANAGEMENT LLC	$165.023.065	2.266.489	4,14%	Saham
ARIEL INVESTMENTS, LLC	$154.572.450	2.060.966	3,88%	Saham
VANGUARD CAPITAL MANAGEMENT LLC	$154.468.350	2.059.578	3,88%	Saham
STATE STREET CORP	$136.363.950	1.818.186	3,42%	Saham
DIMENSIONAL FUND ADVISORS LP	$118.892.744	1.585.222	2,98%	Saham
CITADEL ADVISORS LLC	$113.259.000	1.510.120	2,84%	Saham
GEODE CAPITAL MANAGEMENT, LLC	$96.559.855	1.287.240	2,42%	Saham
River Road Asset Management, LLC	$96.420.150	1.285.602	2,42%	Saham
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$86.651.325	1.155.351	2,18%	Saham
GOLDMAN SACHS GROUP INC	$78.451.463	1.046.019	1,97%	Saham
UBS Group AG	$73.753.350	983.378	1,85%	Saham
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/	$62.319.375	830.925	1,56%	Saham
ROYAL BANK OF CANADA	$58.518.000	780.248	1,47%	Saham
Allspring Global Investments Holdings, LLC	$57.269.232	765.120	1,44%	Saham
DEUTSCHE BANK AG\	$47.374.725	631.663	1,19%	Saham
NORTHERN TRUST CORP	$47.365.650	631.542	1,19%	Saham
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$44.356.725	591.423	1,11%	Saham
Boston Trust Walden Corp	$43.886.100	585.148	1,10%	Saham
MILLENNIUM MANAGEMENT LLC	$42.780.975	570.413	1,07%	Saham
Holocene Advisors, LP	$41.264.625	550.195	1,04%	Saham
SILVERCREST ASSET MANAGEMENT GROUP LLC	$37.034.909	493.796	0,93%	Saham
MORGAN STANLEY	$34.961.254	466.149	0,88%	Saham
BANK OF AMERICA CORP /DE/	$33.326.325	444.351	0,84%	Saham
Boston Partners	$30.395.842	405.892	0,76%	Saham
FRANKLIN RESOURCES INC	$26.060.960	347.479	0,65%	Saham
North Peak Capital Management, LLC	$25.730.775	343.077	0,65%	Saham
LONDON CO OF VIRGINIA	$25.543.299	340.574	0,64%	Saham
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$24.905.625	332.075	0,63%	Saham
VANGUARD FIDUCIARY TRUST CO	$24.779.850	330.398	0,62%	Saham
CITIGROUP INC	$24.002.775	320.037	0,60%	Saham
Aristotle Capital Boston, LLC	$21.721.809	289.624	0,55%	Saham
FMR LLC	$21.604.051	288.054	0,54%	Saham
Bank of New York Mellon Corp	$21.566.396	287.552	0,54%	Saham
MIZUHO MARKETS AMERICAS LLC	$21.166.050	282.214	0,53%	Saham
JPMORGAN CHASE & CO	$17.275.045	227.888	0,43%	Saham
PRINCIPAL FINANCIAL GROUP INC	$16.493.025	219.907	0,41%	Saham
Invenomic Capital Management LP	$16.216.275	216.217	0,41%	Saham
GLENMEDE TRUST CO NA	$15.348.975	204.653	0,39%	Saham
HEARTLAND ADVISORS INC	$15.000.000	200.000	0,38%	Saham
Invesco Ltd.	$12.976.425	173.019	0,33%	Saham
SEI INVESTMENTS CO	$12.546.500	167.274	0,31%	Saham
Longaeva Partners L.P.	$12.286.650	163.822	0,31%	Saham
RHUMBLINE ADVISERS	$10.812.225	144.163	0,27%	Saham
AMERICAN CENTURY COMPANIES INC	$10.613.250	141.510	0,27%	Saham
JANUS HENDERSON GROUP PLC	$10.491.810	186.163	0,26%	Saham
Nuveen, LLC	$10.435.425	139.139	0,26%	Saham

Tampilkan semua 361 pemilik institusional →

Aktivis & pemilik 5%+ 8 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju	Diajukan	Kepemilikan	Status	Tujuan	Pengajuan
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	6 Feb. 2004	·	Pengajuan awal	·	SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	20 Agu 2003	·	Pengajuan awal	·	SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	8 Agu 2003	·	Pengajuan awal	·	SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	24 Juni 2003	·	Pengajuan awal	·	SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	19 Juni 2003	·	Pengajuan awal	·	SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	3 Juni 2003	·	Pengajuan awal	·	SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	27 Mei 2003	·	Pengajuan awal	·	SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan	15 Juni 2001	·	Pengajuan awal	·	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 72 orang dalam · 48 pejabat · 25 direktur

19

Orang Dalam	Peran	Aktivitas terakhir	Saham dimiliki	Beli 12m	Bersih 12m
Christopher Simon,	President & CEO	15 Mei 2026 A	444.704	0	$0
Brian Concannon	President & CEO	15 Sep. 2015 M	147.040	0	$0
James Darecca	EVP, Chief Financial Officer	15 Mei 2026 A	54.444	0	$0
William P. Mr. Burke	EVP, Chief Financial Officer	23 Agu 2021 M	30.291	0	$0
Christopher J Lindop	CFO & EVP Business Development	13 Jan. 2016 A	56.743	0	$0
Ronald J Ryan	VP and CFO	1 Nov. 2006 P	2.101	0	$0
Stewart W Strong	President, Global Hospital	26 Juli 2024 S	18.196	0	$0
Byron Selman	President, Global Markets	25 Okt. 2016 A	23.318	0	$0
Peter M Allen	President, Global Plasma	6 Juli 2015 M	34.102	0	$0
Kelly Michael P	President, Global Markets	11 Nov. 2013 M	10.987	0	$0
Mikael Gordon	President, Global Markets	3 Mei 2012 M	4.442	0	$0
Remi Corlin	President, Asia	8 Agu 2008 M	884	0	$0
Keiko Hattori	President, Haemonetics Japan	1 Mei 2008 P	716	0	$0
Thomas Lawlor	President, Patient Division	28 Nov. 2007 M	0	0	$0
Ryoji Sakai	President, Japan	14 Juni 2007 M	0	0	$0
Ulrich Eckert	President, Europe & Latin Am	1 Nov. 2006 P	890	0	$0
Yutaka Sakurada	President, Japan & Asia	2 Mei 2005 P	2.347	0	$0
Frank Chan	EVP, Chief Operating Officer	15 Mei 2026 A	32.936	0	$0
Kent J Davies	Chief Operating Officer	23 Okt. 2015 S	16.891	0	$0
Farris Maryanne Maunsell	VP, Chief Accounting Officer	5 Juni 2026 F	6.242	0	$0
Laurie A. Miller	SVP, Human Resources	5 Juni 2026 F	40.987	0	$0
Roy Galvin	EVP, Chief Commercial Officer	15 Mei 2026 A	39.882	0	$0
Michelle L Basil	EVP and General Counsel	15 Mei 2026 A	68.829	0	$0
Anila Lingamneni	EVP, Chief Technology Officer	12 Juli 2024 S	21.331	0	$0
Josep Llorens	EVP, Global Manufacturing	28 Mei 2024 F	30.940	0	$0
Dan Goldstein	VP, Corporate Controller	13 Juni 2022 S	4.447	0	$0
Jacqueline Scanlan	SVP, Global Human Resources	7 Juni 2021 S	4.216	0	$0
Said Bolorforosh	EVP, Chief Technology Officer	11 Nov. 2019 S	1.977	0	$0
Neil 122-62-507 Ryding	EVP, Global Manufacturing	7 Juni 2018 S	15.226	0	$0
David Fusco	EVP, Global Human Resources	25 Okt. 2016 A	16.867	0	$0
Sandra Jesse	EVP and Chief Legal Officer	25 Okt. 2016 A	48.166	0	$0
Jonathan White	Chief Science and Technology	26 Okt. 2015 S	30.507	0	$0
Susan M Hanlon	VP Finance	26 Okt. 2015 S	20.464	0	$0
Brian R Burns	EVP, Global QA/RA	23 Okt. 2015 S	16.235	0	$0
Dave Helsel	EVP, Global Manufacturing	13 April 2015 D	13.216	0	$0
Kathleen Mcdaniel	EVP Global Human Resources	28 Agu 2014 S	5.013	0	$0
Warren Nighan JR	EVP, Global QA/RA	24 Juli 2013 A	7.618	0	$0
Joseph J Forish	VP, Human Resources	30 April 2013 P	17.279	0	$0
Phillip John Brancazio	VP, Global Manufacturing	4 Mei 2011 P	3.052	0	$0
Alicia R Lopez	VP, Corporate Affairs	5 April 2011 D	2.815	0	$0
Michael I Ruxin	VP Global Software Strategies	4 Nov. 2010 P	215	0	$0
Brad Nutter	Chairman of the Board	29 Juli 2010 A	10.580	0	$0
Robert B Ebbeling	Vice President, Operations	1 Mei 2009 P	15.849	0	$0
Jan Conneely	VP & GM, Arryx, Inc.	1 Mei 2008 P	1.041	0	$0
William Granville	VP, Manufacturing	1 Mei 2008 P	12.188	0	$0
Mark A Popovsky	VP, Corporate Medical Director	1 Mei 2008 P	4.891	0	$0
Stephen Swenson	VP & General Mgr, Global Plasm	1 Mei 2008 P	3.024	0	$0
William Roche Still	VP & Gen Mrg, Therapeutics Bus	4 Mei 2007 M	4.193	0	$0
Lloyd Emerson Johnson	Direktur	24 Juli 2026 A	15.471	0	$0
Diane M Bryant	Direktur	24 Juli 2026 A	9.664	0	$0
Claire Pomeroy	Direktur	24 Juli 2026 A	19.410	0	$0
Ellen M Zane	Direktur	24 Juli 2026 A	21.911	0	$0
Martin D Madaus	Direktur	24 Juli 2026 A	2.538	0	$0
Mark W Kroll	Direktur	24 Juli 2026 A	27.295	1	$98.784
Michael J Coyle	Direktur	24 Juli 2026 A	17.932	0	$0
Robert E Abernathy	Direktur	24 Juli 2026 A	27.519	0	$0
Charles J Dockendorff	Direktur	24 Juli 2025 A	7.126	0	$0
Catherine M Burzik	Direktur	5 Agu 2022 A	19.545	0	$0
Richard J Meelia	Direktur	4 Feb. 2021 M	32.050	0	$0
Ronald G Gelbman	Direktur	11 Nov. 2019 M	48.384	0	$0
Pedro P Granadillo	Direktur	8 Nov. 2018 S	15.335	0	$0
Susan Bartlett Foote	Direktur	10 Nov. 2017 M	20.740	0	$0
Ronald Merriman	Direktur	22 Mei 2017 M	17.807	0	$0
Lawrence C Best	Direktur	12 Juni 2014 M	10.001	0	$0
Paul Black	Direktur	24 Juli 2013 A	8.981	0	$0
Ronald A Matricaria	Direktur	5 Mei 2006 A	·	0	$0
Benjamin L Holmes	Direktur	31 Jan. 2005 M	·	0	$0
Donna C E Williamson	Direktur	23 Juni 2004 M	1.300	0	$0
Harvey G Klein	Direktur	5 Mei 2004 A	·	0	$0
Anthony Pare	·	30 Juni 2008 M	2.523	0	$0
James O'Shaughnessy	·	1 Mei 2008 P	3.781	0	$0
Mark Beucler	·	1 Mei 2008 P	1.989	0	$0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 65 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana	Bobot	Unit	Per tanggal	Sumber
JSML · Janus Detroit Street Trust	1,11%	46.966 NS	31 Juli 2026	N-PORT
JSMD · Janus Detroit Street Trust	0,91%	112.014 NS	31 Juli 2026	N-PORT
ROSC · Lattice Strategies Trust	0,85%	6.121 NS	31 Juli 2026	N-PORT
DWAS · Invesco Exchange-Traded Fund Trust …	0,37%	14.249 SH	2 Okt. 2026	Harian
FYC · First Trust Exchange-Traded AlphaDE…	0,31%	46.806 NS	31 Juli 2026	N-PORT
IWO · iShares Trust	0,30%	419.058 SH	11 Sep. 2026	Harian
PRFZ · Invesco Exchange-Traded Fund Trust	0,27%	68.060 SH	2 Okt. 2026	Harian
VTWG · VANGUARD SCOTTSDALE FUNDS	0,20%	47.624 SH	19 Agu 2026	Harian
BKSE · BNY Mellon ETF Trust	0,17%	1.770 NS	31 Juli 2026	N-PORT
JPSE · J.P. Morgan Exchange-Traded Fund Tr…	0,16%	11.309 NS	31 Juli 2026	N-PORT
QVMM · Invesco Exchange-Traded Fund Trust …	0,16%	6.183 SH	2 Okt. 2026	Harian
IWM · iShares Trust	0,16%	1.206.787 SH	11 Sep. 2026	Harian
SMDX · Tidal Trust III	0,15%	2.335 NS	31 Juli 2026	N-PORT
NUSC · Nushares ETF Trust	0,15%	23.101 NS	31 Juli 2026	N-PORT
PKW · Invesco Exchange-Traded Fund Trust	0,15%	24.033 SH	2 Okt. 2026	Harian
BBSC · J.P. Morgan Exchange-Traded Fund Tr…	0,15%	12.150 NS	31 Juli 2026	N-PORT
FSMD · FIDELITY COVINGTON TRUST	0,15%	43.448 NS	31 Juli 2026	N-PORT
RSSL · Global X Funds	0,13%	22.588 NS	31 Juli 2026	N-PORT
IVOG · VANGUARD ADMIRAL FUNDS	0,11%	27.512 SH	19 Agu 2026	Harian
VTWO · VANGUARD SCOTTSDALE FUNDS	0,11%	271.486 SH	19 Agu 2026	Harian
EBIT · Harbor ETF Trust	0,11%	154 NS	31 Juli 2026	N-PORT
PTMC · Pacer Funds Trust	0,11%	5.030 NS	31 Juli 2026	N-PORT
ESML · iShares Trust	0,11%	29.599 SH	11 Sep. 2026	Harian
DFAT · Dimensional ETF Trust	0,10%	173.703 NS	31 Juli 2026	N-PORT
IVOO · VANGUARD ADMIRAL FUNDS	0,10%	74.976 SH	19 Agu 2026	Harian
MIDU · Direxion Shares ETF Trust	0,09%	682 NS	31 Juli 2026	N-PORT
DFAS · Dimensional ETF Trust	0,08%	150.472 NS	31 Juli 2026	N-PORT
IVOV · VANGUARD ADMIRAL FUNDS	0,08%	15.968 SH	19 Agu 2026	Harian
FYX · First Trust Exchange-Traded AlphaDE…	0,07%	11.631 NS	31 Juli 2026	N-PORT
FAD · First Trust Exchange-Traded AlphaDE…	0,06%	4.239 NS	31 Juli 2026	N-PORT
FHLC · FIDELITY COVINGTON TRUST	0,06%	22.085 NS	31 Juli 2026	N-PORT
ISCG · iShares Trust	0,06%	5.407 SH	11 Sep. 2026	Harian
RWK · Invesco Exchange-Traded Fund Trust …	0,06%	6.859 SH	2 Okt. 2026	Harian
VBK · VANGUARD INDEX FUNDS	0,05%	302.003 SH	19 Agu 2026	Harian
VHT · VANGUARD WORLD FUND	0,05%	139.826 SH	19 Agu 2026	Harian
WSML · iShares Trust	0,05%	3.039 SH	11 Sep. 2026	Harian
VXF · VANGUARD INDEX FUNDS	0,04%	533.077 SH	19 Agu 2026	Harian
VB · VANGUARD INDEX FUNDS	0,04%	1.042.525 SH	19 Agu 2026	Harian
VBR · VANGUARD INDEX FUNDS	0,04%	331.074 SH	19 Agu 2026	Harian
DXUV · Dimensional ETF Trust	0,03%	2.112 NS	31 Juli 2026	N-PORT
DFUV · Dimensional ETF Trust	0,02%	40.194 NS	31 Juli 2026	N-PORT
DFAC · Dimensional ETF Trust	0,02%	104.425 NS	31 Juli 2026	N-PORT
DFSU · Dimensional ETF Trust	0,02%	4.745 NS	31 Juli 2026	N-PORT
DCOR · Dimensional ETF Trust	0,02%	6.430 NS	31 Juli 2026	N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe…	0,02%	392 SH	2 Okt. 2026	Harian
DFAU · Dimensional ETF Trust	0,01%	14.641 NS	31 Juli 2026	N-PORT
VTWV · VANGUARD SCOTTSDALE FUNDS	0,01%	2.320 SH	19 Agu 2026	Harian
ESGV · VANGUARD WORLD FUND	0,01%	10.376 SH	19 Agu 2026	Harian
IUSG · iShares Trust	0,01%	23.921 SH	11 Sep. 2026	Harian
IWV · iShares Trust	0,01%	14.081 SH	11 Sep. 2026	Harian
ITOT · iShares Trust	0,01%	61.263 SH	11 Sep. 2026	Harian
DFUS · Dimensional ETF Trust	0,01%	15.447 NS	31 Juli 2026	N-PORT
IUSV · iShares Trust	0,01%	16.215 SH	11 Sep. 2026	Harian
TILT · FlexShares Trust	0,00%	948 NS	31 Juli 2026	N-PORT
VTI · VANGUARD INDEX FUNDS	0,00%	1.441.997 SH	19 Agu 2026	Harian
VT · VANGUARD INTERNATIONAL EQUITY INDEX…	0,00%	37.682 SH	19 Agu 2026	Harian
VTHR · VANGUARD SCOTTSDALE FUNDS	0,00%	3.899 SH	19 Agu 2026	Harian
IJH · iShares Trust	·	1.630.595 SH	11 Sep. 2026	Harian
IJK · iShares Trust	·	161.240 SH	11 Sep. 2026	Harian
IJJ · iShares Trust	·	94.617 SH	21 Agu 2026	Harian
IWN · iShares Trust	·	24.317 SH	11 Sep. 2026	Harian
XJH · iShares Trust	·	6.379 SH	8 Sep. 2026	Harian
ISCB · iShares Trust	·	2.011 SH	11 Sep. 2026	Harian
ISCV · iShares Trust	·	6.131 SH	11 Sep. 2026	Harian
SMLF · iShares Trust	·	28.971 SH	11 Sep. 2026	Harian

HAE Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21

peringkat · 15 analis BELI

Target median $116.50 +11,3%

5 33,3% Beli Kuat

6 40,0% Beli

4 26,7% Tahan

0 0,0% Jual

0 0,0% Jual Kuat

Target Harga 12 Bulan

10 analis · 2026-10-01

Target rata-rata $111.50 +6,5%

Sekarang Harga saat ini $104.68

Rendah$86.00 Rata-rata$111.50 Tinggi$125.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker	Kapitalisasi Pasar	P/E	Pendapatan YoY	Margin Bersih	ROE	Margin Kotor
HAE	$2.45B	26.4	-2.0%	7.3%	11.8%	59.0%
COO	$13.70B	37.4	5.1%	9.2%	4.6%	65.5%
ALGN	$11.14B	27.6	0.90%	10.2%	10.3%	67.2%
LNTH	$4.30B	19.5	0.50%	15.2%	20.7%	61.1%
MMED	$3.71B	-10.2	14.2%	-10.7%	-9.3%	54.2%
MMSI	$5.24B	41.4	11.8%	8.5%	8.4%	48.7%
QDEL	$1.99B	-1.8	-1.9%	-41.4%	-48.0%	·
ICUI	$3.52B	4755.7	-6.3%	0.03%	0.03%	36.8%
XRAY	$2.28B	-3.8	-3.0%	-16.2%	-36.4%	50.0%
NEOG	$1.95B	-224.2	-2.7%	-0.91%	-0.38%	46.9%
UFPT	$1.71B	25.4	19.5%	11.3%	16.9%	28.3%

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

23

Sorotan Panggilan Pendapatan Kuartal 4 Haemonetics Yahoo Finance · 4 bulan, 3 minggu lalu Strategi Nilai Berkelanjutan Riverwater Menunggu Validasi Pasar Haemonetics Corporation (HAE) Yahoo Finance · 5 bulan, 1 minggu lalu

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

HAE Haemonetics Corporation Common Stock

HAE Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

HAE Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

Tentang Haemonetics Corporation Common Stock Tinjauan perusahaan dari Wikipedia

History

Product categories

Hemostasis

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC

Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca

Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T

Metrik Per Saham EPS, nilai buku per saham, arus kas per saham, dividen per saham

Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

Pemilik institusional (13F) 361 pengaju · $4.0B total · Per tanggal 30 Sep. 2026

Aktivis & pemilik 5%+ 8 saham

Orang dalam perusahaan 72 orang dalam · 48 pejabat · 25 direktur

Kepemilikan ETF Dimiliki oleh 65 ETF

HAE Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

Target Harga 12 Bulan

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap